NTLA — Intellia Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.55bn
- $1.10bn
- $67.67m
Annual income statement for Intellia Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 33.1 | 52.1 | 36.3 | 57.9 | 67.7 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 301 | 510 | 552 | 592 | 509 |
| Operating Profit | -268 | -458 | -515 | -534 | -441 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -268 | -474 | -481 | -519 | -413 |
| Net Income After Taxes | -268 | -474 | -481 | -519 | -413 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -268 | -474 | -481 | -519 | -413 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -268 | -474 | -481 | -519 | -413 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.78 | -6.16 | -5.42 | -5.25 | -3.81 |